Wednesday 6-18-2014 Gilead Sciences (GILD) $GILD o
Post# of 162
Posted On: 06/18/2014 9:25:14 PM
Wednesday 6-18-2014 Gilead Sciences (GILD) $GILD opened at 79.85 hitting the high price of 79.99 and a day low of 78.83 with a total volume of 12,003,035. GILD had a previous close of 79.79 and has been seeing an average volume of 10,232,540.
Overall Average: 8% Sell
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Growing Insurer Centene Embraces Affordable Care Act
at Investor's Business Daily - 2 hrs 50 mins ago
The Affordable Care Act (ACA) has taken its share of criticism since its October launch, but health insurer Centene (CNC) is poised for strong growth because of it. The company's primary focus is the Medicaid managed-care business, which it conducts... (full story)
Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641). (full story)
Final Glance: Biotechnology companies
AP - Wed Jun 18, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab. (full story)
Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
Alexion's Soliris Gets Orphan Drug Status for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 10:30AM CDT
The FDA granted Alexion's (ALXN) Soliris Orphan Drug Status for MG. (full story)
Pfizer Ties Up with Cellectis for Cancer Immunotherapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 10:10AM CDT
Pfizer entered into an agreement with Cellectis to develop chimeric antigen receptor CAR-T immunotherapies directed at select targets. (full story)
AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:46AM CDT
AVEO Pharmaceuticals (AVEO) was a big mover last session, with shares rising over 11% on the day. (full story)
The Zacks Analyst Blog Highlights: DreamWorks Animation, Netflix, Valeant Pharmaceuticals International, Allergan, Gilead Sciences and ForestLaboratories
PR Newswire - Wed Jun 18, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the DreamWorks Animation SKG Inc. (Nasdaq
WA-Free Report), Netflix Inc. (Nasdaq:NFLX-Free Report), News Corp. (Nasdaq:NWSA-Free Report), Valeant Pharmaceuticals International, Inc. (NYSE:VRX-Free Report), Allergan, Inc. (NYSE:AGN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report) and Forest Laboratories Inc. (NYSE:FRX-Free Report). (full story)
Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been... (full story)
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported... (full story)
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association. (full story)
Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:00PM CDT
An analyst estimates that two pivotal phase III studies (TRAFFIC and TRANSPORT) on Vertex Pharmaceuticals Incorporated's (VRTX) combination cystic fibrosis therapy are more likely to fail. (full story)
Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:47PM CDT
Novartis (NVS) announced the submission of its BLA for meningitis B vaccine candidate Bexsero to the FDA for marketing approval among adolescents and young adults within the age group of 10 to 25 years. (full story)
Glaxo's Promacta Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:45PM CDT
GlaxoSmithKline (GSK) announced encouraging results from the phase III PETIT2 study on Promacta. (full story)
After Yesterday's Decline of 1.21%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 17, 3:39PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.56 to a high of $80.87. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $79.87 on volume of 11.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.21% Loss
Comtex SmarTrend(R) - Tue Jun 17, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.56 to a high of $80.87. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $79.87 on volume of 11.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:35PM CDT
Ligand Pharmaceuticals Inc. (LGND) announced positive data from a phase I study on its type II diabetes candidate, LGD-6972. (full story)
Overall Average: 8% Sell
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Growing Insurer Centene Embraces Affordable Care Act
at Investor's Business Daily - 2 hrs 50 mins ago
The Affordable Care Act (ACA) has taken its share of criticism since its October launch, but health insurer Centene (CNC) is poised for strong growth because of it. The company's primary focus is the Medicaid managed-care business, which it conducts... (full story)
Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641). (full story)
Final Glance: Biotechnology companies
AP - Wed Jun 18, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading: (full story)
Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab. (full story)
Midday Glance: Biotechnology companies
AP - Wed Jun 18, 1:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.: (full story)
Early Glance: Biotechnology companies
AP - Wed Jun 18, 10:36AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
Alexion's Soliris Gets Orphan Drug Status for New Indication - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 10:30AM CDT
The FDA granted Alexion's (ALXN) Soliris Orphan Drug Status for MG. (full story)
Pfizer Ties Up with Cellectis for Cancer Immunotherapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 10:10AM CDT
Pfizer entered into an agreement with Cellectis to develop chimeric antigen receptor CAR-T immunotherapies directed at select targets. (full story)
AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:46AM CDT
AVEO Pharmaceuticals (AVEO) was a big mover last session, with shares rising over 11% on the day. (full story)
The Zacks Analyst Blog Highlights: DreamWorks Animation, Netflix, Valeant Pharmaceuticals International, Allergan, Gilead Sciences and ForestLaboratories
PR Newswire - Wed Jun 18, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the DreamWorks Animation SKG Inc. (Nasdaq
WA-Free Report), Netflix Inc. (Nasdaq:NFLX-Free Report), News Corp. (Nasdaq:NWSA-Free Report), Valeant Pharmaceuticals International, Inc. (NYSE:VRX-Free Report), Allergan, Inc. (NYSE:AGN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report) and Forest Laboratories Inc. (NYSE:FRX-Free Report). (full story) Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been... (full story)
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported... (full story)
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:20PM CDT
Johnson & Johnson (JNJ) presented encouraging data from a phase III study on its oncology drug, Velcade, at the annual meeting of the European Hematology Association. (full story)
Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 4:00PM CDT
An analyst estimates that two pivotal phase III studies (TRAFFIC and TRANSPORT) on Vertex Pharmaceuticals Incorporated's (VRTX) combination cystic fibrosis therapy are more likely to fail. (full story)
Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:47PM CDT
Novartis (NVS) announced the submission of its BLA for meningitis B vaccine candidate Bexsero to the FDA for marketing approval among adolescents and young adults within the age group of 10 to 25 years. (full story)
Glaxo's Promacta Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:45PM CDT
GlaxoSmithKline (GSK) announced encouraging results from the phase III PETIT2 study on Promacta. (full story)
After Yesterday's Decline of 1.21%, Gilead Sciences Offers Investors Better Value
Comtex SmarTrend(R) - Tue Jun 17, 3:39PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.56 to a high of $80.87. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $79.87 on volume of 11.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
SmarTrend Watching for Potential Rebound in Shares of Gilead Sciences After 1.21% Loss
Comtex SmarTrend(R) - Tue Jun 17, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $79.56 to a high of $80.87. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $79.87 on volume of 11.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 17, 3:35PM CDT
Ligand Pharmaceuticals Inc. (LGND) announced positive data from a phase I study on its type II diabetes candidate, LGD-6972. (full story)
(0)
(0)Gilead Sciences Inc. (GILD) Stock Research Links
Scroll down for more posts ▼